Rationale and design of TransplantLines: a prospective cohort study and biobank of solid organ transplant recipients. Issue 12 (31st December 2018)

• Record Type: Journal Article
• Authors: Eisenga, Michele F; Gomes-Neto, Antonio W; van Londen, Marco; Ziengs, Aaltje L; Douwes, Rianne M; Stam, Suzanne P; Osté, Maryse C J; Knobbe, Tim J; Hessels, Niek R; Buunk, Anne M; Annema, Coby; Siebelink, Marion J; Racz, Emoke; Spikman, Jacoba M; Bodewes, Frank A J A; Pol, Robert A; Berger, Stefan P; Drost, Gea; Porte, Robert J; Leuvenink, Henri G D; Damman, Kevin; Verschuuren, Erik A M; de Meijer, Vincent E; Blokzijl, Hans; Bakker, Stephan J L
• Is Part Of: BMJ open. Volume 8:Issue 12(2018)
• Publication Date: 2018-12-31
• Subjects: cohort study -- transplant medicine -- survival; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2018-024502
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: In the past decades, short-term results after solid organ transplantation have markedly improved. Disappointingly, this has not been accompanied by parallel improvements in long-term outcomes after transplantation. To improve graft and recipient outcomes, identification of potentially modifiable risk factors and development of biomarkers are required. We provide the rationale and design of a large prospective cohort study of solid organ transplant recipients (TransplantLines). Methods and analysis: TransplantLines is designed as a single-centre, prospective cohort study and biobank including all different types of solid organ transplant recipients as well as living organ donors. Data will be collected from transplant candidates before transplantation, during transplantation, at 3 months, 6 months, 1 year, 2 years and 5 years, and subsequently every 5 years after transplantation. Data from living organ donors will be collected before donation, during donation, at 3 months, 1 year and 5 years after donation, and subsequently every 5 years. The primary outcomes are mortality and graft failure. The secondary outcomes will be cause-specific mortality, cause-specific graft failure and rejection. The tertiary outcomes will be other health problems, including diabetes, obesity, hypertension, hypercholesterolaemia and cardiovascular disease, and disturbances that relate to quality of life, that is, physical and psychological functioning, including quality of sleep, and neurological problems such as tremor and polyneuropathy. Ethics and dissemination: Ethical approval has been obtained from the relevant local ethics committee. The TransplantLines cohort study is designed to deliver pioneering insights into transplantation and donation outcomes. The study design allows comprehensive data collection on perioperative care, nutrition, social and psychological functioning, and biochemical parameters. This may provide a rationale for future intervention strategies to more individualised, patient-centred transplant care and individualisation of treatment. Trial registration number: NCT03272841 .